B-66/100

Is Natera Inc (NTRA) a risky stock?

Sector: Biotechnology Price: $266.42 Composite: 66/100

As of July 21, 2026, Clavix grades Natera Inc (NTRA) B- for risk, a composite score of 66 out of 100 on an A+ to F scale, which puts NTRA in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.

Grade as of July 21, 2026. Clavix regrades every trading day.

The five risk dimensions behind NTRA's grade

Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how NTRA scores on each, as of July 21, 2026.

Financial healthbalance sheet, margins, cash flow
56
News sentimentscored, sourced recent coverage
58
Macro exposuresensitivity to rates, dollar, oil
71
Sector resiliencestrength vs the broad market
67
Price stabilitydrawdown and volatility
40

What's moving NTRA's risk right now

Company-specific signals Clavix flags behind NTRA's current grade, drawn from recent news and filings as of July 21, 2026.

Regulatory · mixed signal

Pending regulatory outcomes could shift materially in either direction, keeping uncertainty elevated in the risk premium.

Technical setup · supporting the grade

Price structure and relative strength suggest accumulation, which often precedes fundamental re-rating catalysts.

Earnings & results · mixed signal

It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months. He's a retired hedge fund manager, but people still want to know what bi…

What a B- grade means

On the Clavix A+ to F scale, NTRA's composite of 66 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.

A+AA-B+BB-C+CC-D+DD-F
Get Clavix on iPhone → Or grade your whole portfolio free, no account needed.

This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell NTRA or any security. Grades are risk indicators, not predictions of return. Data may be delayed.